Haixi Pharma adheres to the development philosophy of "Generics empower innovation, innovation drives the future", and has launched R&D programs in therapeutic areasincluding oncology, endocrinology, psychiatry, cardiovascular, and gastroenterology.

   For innovative drug development,  we focus on developing small molecules drugs with clear medical needs and global market potential  mainly in tumor immunotherapy, autoimmune diseases, and metabolic disorders. We have established a small molecule innovative drug  R&D platform, including medicinal chemistry, biology, formulation, DMPK and CMC. At the same time, the company makes full use of Fujian’s clinical trial resources, establishing cooperative relationships to advance  clinical trial studies in humans. The leading project, C019199, is about to enter Phase III clinical trials, with multiple trials in progress for different indications, both as monotherapy and in combination. Other projects are moving forward  for IND (Clinical Trial) applications.

   For generic drugs, we focus on developing those first-to-market, difficult-to-duplicate  and high-value generics. As of October 2025, 15 products have received marketing approval  from the NMPA. Several other products are under development at different stages, including laboratory research, process scale-up, and bioequivalent (BE) studies.

Patent technology

   The company attaches great importance to intellectual property protection throughout the R&D process. As of October 2025, Haixi has been granted over 30 invention patents.

Industry-University-Research Collaboration

   The company actively engages in university-enterprise cooperation and serves as an internship base for Fuzhou University, Fujian Medical University, and Minjiang University. It also works closely with  Peking University and Xiamen University, and other institutions to carry out scientific research.